CD44V6在肺鳞癌中的表达

目的 探讨CD44V6在肺鳞癌中的表达及其与肺鳞癌发生发展的相关性 。方法 应用免疫组织化学ABC法检测35例手术切除的新鲜肺鳞组织及 其癌旁正常肺组织的CD44V6蛋白,并将检测结果与患者的临床病理资料进行对照分析。结果 CD44V6在肺磷癌组织中的阳性表达率为65．7％（23／35）,而在癌旁正常肺组织中则无表达,二者差异有显著性（X^2=34．3,P＜0．01）;CD44V6在有淋巴结转移的肺鳞癌组织中的阳性表达率（84．2％,16／19）明显高于其在无淋巴结转移中的阳性表达率（43．8％,7／16）（X^2＝6．3,P＜0．01）;CD44V6阳性表达率随肺鳞癌组织分化程度的降低而或高,但无统计学意义（X^2=2．33,P＞0．05）;CD44V6在Ⅲ Ⅳ期肺鳞癌中的阳性表达率（86．7％,13／15）明显高于其在Ⅰ Ⅱ期中的阳性表达率（50％,10／20）,（X^2＝5．1,P＜0．01）;CD44V6阳性表达患者的3年生存率（30．4％,7／23）明显低于CD44V6阴性者（66．7％,8／12）（X^2＝4．2,P＜0．05）。结论 CD44V6可能与肺鳞癌的发生有关;CD44V6阳性预示肺鳞癌可能发生淋巴结转移,并对肺鳞癌的临床分期起到一定作用;CD44V6阳性还可作为评估肺鳞癌患者预后的参考指标。     

阴道斜隔综合征诊治分析

目的探讨阴道斜隔综合征的临床特点、诊断及治疗方法。方法对1996年～2005年我院收治的8例阴道斜隔综合征患者进行回顾性分析。结果8例患者均行阴道斜隔切开术,2002年前仅1例患者术后6年切缘粘连、复发。2002年后均采用腹腔镜联合宫腔镜手术,术后无1例复发。结论阴道斜隔综合征临床表现复杂、多变,无特异性,主要由隔后腔积血、积脓、引流不畅、梗阻而诱发一系列症状。只要正确认识本病,诊断不难。阴道斜隔综合征一旦确诊,首选阴道斜隔切除并引流术。术后生育功能同正常妇女。     

Apoptosis of neoplasm cell lines induced by hepatic peptides extracted from sucking porcine hepatocytes

lNTRODUCTlONPromotinghepatocytegr0wthfact0r(pHGF)extractedfromthesuckingpigliverisaseriesofpolypeptideswithmolecularweightlessthanM,100O0andhasspecificbiol0gicalactivitiest0stimulatetherathepatocyteDNAsynthesisafter1/3partialhepatectomyandpromoterecoveryofrathepaticinjuriesinducedbyend0toxinandD-aminogalatose.ThesepropertiesaresimilartotheresultsreportedbyLabrecque['].pHGFcaneffectivelycureclinicalacutefulminanthepatitis,chronichepatitisand0therhepaticinjuriesbysignificantlyreducingser…     

毒物分析用于1例苯巴比妥中毒患者抢救

目的：为临床提供大剂量苯巴比妥中毒患者血药浓度与临床症状的关系。方法;介绍一例进行中毒药物测定的患者,报告并解释其抢救过程血药浓度与相应的临床症状。结果：中毒患者在血药浓度指导下,成功地采用血液灌流进行抢救。结论：毒物分析能有效指导临床苯巴比妥中毒患者抢救,血药浓度与临床症状密切相关。     

HPLC法测定血清中司帕沙星的浓度

采用HPLC法测定血清中司帕沙星的浓度。血清标本经甲醇沉淀蛋白,高速离心后取上清液直接进样。色谱条件以PE-pack C_(18)柱(5μm,4.6mm×150mm)为色谱柱,甲醇-0.2mol·L~(-1)乙酸铵溶液(pH2.7)(30:70)为流动相,检测波长为298nm血清中药物的最低检测浓度为0.04μg·ml~(-1)。在0.05～2μg·ml~(-1)血药浓度范围内峰高与药物浓度线性关系良好,Y=5.835 1X-0.030 6,r=0.999 3。相对回收率为91.9％～103.4％,绝对回收率为91.5％～93.6％。日内RSD为1.5％～1.9％,日间RSD为1.9％～4.5％。方法简单、快速、准确,可用于司帕沙星的临床药动学研究。     

A triterpenoid saponin from Albizia julibrissin

A triterpenoid saponin (1) was obtained from the stem barks of Albizia julibrissin Durazz. Its structure was elucidated as 3-O-[beta-D-xylopyranosyl-(1 --> 2)-alpha-L-arabinopyranosyl-(1 --> 6)-beta-D-glucopyranosyl]-21-O-[(6S)-2-trans-2-hydroxymethyl-6-methyl-6-O-beta-D-quinovopyranosyl-2, 7-octadienoyl]-16-deoxy-acacic acid 28-O-beta-D-glucopyranosyl-(1 --> 3)-[alpha-L-arabinofuranosyl-(1 --> 4)]-alpha-L-rhamnopyranosyl-(1 --> 2)-beta-D-glucopyranosyl ester (1), named as Julibroside J26, based on the chemical and spectral methods.     

司帕沙星与其他5种抗菌药体外抗菌活性比较研究

测定了司帕沙星对临床分离的１９９ 株致病菌的体外抗菌活性并与氧氟沙星、环丙沙星、头孢唑啉、头孢噻肟、阿米卡星的抗菌活性进行比较。司帕沙星对革兰阳性菌的ＭＩＣ９０为０．１２５～０．５ｍ ｇ／Ｌ,对金葡球菌、化脓链球菌的抑菌率均为１００％ ,强于氧氟沙星、环丙沙星;对革兰阴性菌也具有良好的体外抗菌活性,与氧氟沙星、环丙沙星相似。不同细菌接种量和不同浓度血清对其抗菌活性无明显影响,仅在ｐＨ５．０ 时抗菌活性略有下降     

龙马酶的固定化研究

研究龙马酶（ＥＣ ３． １． １． ３）固定化载体、固定化条件和固定化酶的性质。方法：固定化采用吸附法。结果：固定化最适条件：酶液ＰＨ９．０,吸附时间１．５ ｈ,酶浓度１．５ ｇ／１００ ｍｌ,在此条件下固定化酶活力５３ ｕ／ｇ载体,活力回收率７１％。固定化酶的最适作用温度和ｐＨ较游离酶高,范围较游离酶广,耐热性、酸碱稳定性比游离酶好。结论：固定化酶性能比游离酶得到提高。     

表达重组人红细胞生成素细胞株的高密度、高表达培养

用生物反应器培养能表达重组人红细胞生成素的工程细胞,使其达到高密度高表达。方法：先将工程细胞在含有５％胎牛血清的 ＤＭＥＭ－Ｆ１２培养基中培养,待细胞总数达到 ２×１０~８个以上时,接种到５ Ｌ生物反应器中。用含有血清的培养基培养 ７ｄ后转为无血清ＣＨＯ专用培养基,继续培养 ３０ ｄ。在整个培养过程中,采用流加的方式连续培养,根据情况随时测定培养基中葡萄糖浓度,使其保持高于０．５ｇ／Ｌ,同时监测氨及乳酸盐浓度,避免浓度过高。每日采样测定收获液中红细胞生成素含量与活性,培养结束后,以０．２５％胰酶消化载体,待细胞全部脱落后计数细胞总量。 结果：细胞密度达 ６×１０~６个／ｍｌ培养液,表达量约 ３０ ０００ ＩＵ／ｍｌ左右,且表达的红细胞生成素具有较高的生物比活性。结论：在较为适当的培养条件下,利用生物反应器可使工程细胞的培养达到高密度、高表达。     

Low prevalence of the APC I1307K sequence in Jewish and non-Jewish patients with inflammatory bowel disease.

A germline sequence alteration at codon 1307 of the APC gene (I1307K) has been reported in 6-7% of the Ashkenazi Jewish population in the United States. This alteration is believed to predispose the APC gene to a secondary mutation at the same locus, resulting in an increased risk of colorectal carcinoma. There is an increased risk of colorectal carcinoma in patients with inflammatory bowel disease (IBD), a relatively large proportion of whom are Ashkenazi Jews. We therefore sought to determine whether the I1307K sequence variant occurred in the germline DNA of IBD patients. To our surprise, we found this sequence in only two of 267 patients with IBD (0.7%), occurring in only 1.5% of Jewish IBD patients. The I1307K sequence variant was not found in 67 patients with esophageal cancer, 53 patients with gastric carcinoma (13 MSI-H and 44 MSI-negative), or ten patients with sporadic MSI-H colon cancer. These findings suggest that the I1307K sequence is relatively rare in the germline of Jewish as well as non-Jewish IBD patients. It does not appear to contribute to the increased colorectal cancer risk present in these patients.